CJ Bio's 'NOVOSIS' Receives Seven-Year Re-examination Compliance Approval from Ministry of Food and Drug Safety
CJ Bio, a company specializing in regenerative medicine, announced on July 9 that its bone substitute 'NOVOSIS' has successfully completed a seven-year Post-Market Surveillance (PMS) conducted by the Ministry of Food and Drug Safety and has received approval for re-examination compliance.
This re-examination result signifies that the safety and efficacy of NOVOSIS have once again been confirmed through data accumulated over a long period in real clinical settings. Notably, during the seven-year investigation period, there were no unexpected serious medical device adverse events, and no new safety issues were identified.
The PMS is a system in which the safety and efficacy of newly developed medical devices are continuously evaluated in actual medical settings among diverse patient groups after the product has been approved. It is a core procedure of full-cycle safety management for medical devices, verifying long-term safety and clinical performance in real-world environments, which are difficult to determine in pre-approval clinical trials. In particular, for bone substitutes implanted in the body to induce bone formation, long-term post-market safety management is even more critical, as treatment outcomes may vary depending on the patient's health status, the location and size of the bone defect, and the surgical method.
The PMS for NOVOSIS was conducted over a total of seven years, from June 29, 2017, the product's approval date, to June 28, 2024, marking the longest investigation period among newly developed medical devices subject to re-examination. CJ Bio completed the analysis of the collected data and the final investigation report after the study ended and received re-examination compliance approval from the Ministry of Food and Drug Safety on May 18, 2026.
This PMS involved a total of 28 researchers from 20 medical institutions nationwide and included long-term follow-up in real clinical settings for 860 patients. The subjects consisted of 511 patients who underwent posterolateral spinal fusion and 349 patients who received bone defect filling due to acute upper or lower extremity fractures. Baseline information, medical history, surgical information, concomitant medications, and occurrence of adverse events were systematically collected, and a safety management system was in place to ensure immediate reporting of any serious adverse events.
As a result of the safety evaluation, medical device adverse events occurred in only 6 out of 860 patients (0.70%, 10 cases), indicating a very low incidence rate. By indication, adverse events occurred in 0.59% of posterolateral spinal fusion cases and 0.86% of acute upper or lower extremity fracture bone defect filling cases. There were no unexpected serious adverse events related to the medical device.
Overall, adverse events were reported in 89 patients (10.35%, 159 cases), but most were common postoperative complications. Serious adverse events were observed in 35 patients (4.07%, 43 cases), but all were within the expected range as previously identified in the approval clinical trials, and no new safety signals were found.
Excellent results were also confirmed in the efficacy evaluation. In all approved indications, NOVOSIS demonstrated a high bone union rate of approximately 98% in clinical practice, proving its stable bone-forming efficacy. Among posterolateral spinal fusion patients, the bone union rate was 97.48% based on a 3D CT scan 12 months after the procedure, while patients who underwent bone defect filling for acute upper or lower extremity fractures showed a 98.13% bone union rate based on a simple X-ray taken 12 months after the procedure.
NOVOSIS is a bone substitute that combines 100% hydroxyapatite (HA) ceramics, which provide osteoconductivity, with recombinant human bone morphogenetic protein-2 (rhBMP-2), which promotes osteoinduction. It is approved for use in single-level posterolateral fusion following lumbar posterior instrumentation and for bone defects of 5cm or less due to acute upper or lower extremity fractures. It may be used at the clinician's discretion when autologous bone harvesting is difficult or insufficient.
CJ Bio plans to use this re-examination approval as an opportunity to support proper use within the approved indications, continue ongoing post-market safety information management, and actively utilize the extensive domestic multi-center clinical data accumulated over the past seven years in applications to the US FDA PMA, European PMCF (Post-Market Clinical Follow-up), and other global regulatory agencies to further accelerate global market entry.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Hyunseung Yoo, CEO of CJ Bio, stated, "This re-examination approval is a significant achievement that demonstrates the long-term safety and efficacy of NOVOSIS in real clinical settings. Based on the accumulated PMS data, we will further enhance trust among domestic and international healthcare professionals and actively pursue global clinical and regulatory strategies, including the US FDA PMA and European PMCF, to continuously strengthen our competitiveness in the global regenerative medicine market."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.